# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- describe cancer treatment challenges
- discuss epigenetic regulation and CARM1

## SUMMARY OF THE INVENTION

- summarize method of treating cancer
- list EZH2 inhibitors and platinum drugs

## DETAILED DESCRIPTION OF THE INVENTION

- define terms and phrases used in the invention

### Definitions

- define co-administration and related terms
- define active pharmaceutical ingredient and drug
- define effective amount and therapeutically effective amount
- define prodrug and related terms

### Methods of Treating Cancers and Other Diseases

- describe methods of treating diseases using compositions and methods of the invention

### EZH2 Inhibitors

- describe EZH2 inhibitors and their use in treating cancer
- describe specific EZH2 inhibitors, including GSK126, GSK503, and others
- describe additional EZH2 inhibitors and their properties

### Platinum-Based Antineoplastic Drugs

- define platinum-based antineoplastic drugs
- describe embodiments

### Pharmaceutical Compositions

- define pharmaceutical composition
- specify concentration of active pharmaceutical ingredients
- specify amount of active pharmaceutical ingredients
- describe molar ratio of active pharmaceutical ingredients
- describe pharmaceutical compositions for oral administration
- describe pharmaceutical compositions for injection
- describe pharmaceutical compositions for injectable solutions
- formulate pharmaceutical compositions for topical delivery
- prepare pharmaceutical compositions for inhalation
- describe other pharmaceutical compositions
- administer pharmaceutical compositions
- provide kits for pharmaceutical compositions

### Dosages and Dosing Regimens

- specify dosage ranges
- describe administration schedules
- provide examples of effective dosages
- outline administration routes

## EXAMPLES

- illustrate embodiments

### Example 1—CARM1 is Associated with Poor Prognosis in Ovarian Cancer Patients

- associate CARM1 with poor prognosis

### Example 2—CARM1-Expressing Cells are Sensitive to the EZH2 Inhibitor GSK126

- demonstrate sensitivity to GSK126

### Example 3—CARM1 Depletion Abrogates GSK126 Sensitivity in CARM1-Expressing Cells

- confirm CARM1-EZH2 relationship

### Example 4—CARM1-Expressing Ovarian Cancer Depends on the Histone Methyltransferase EZH2 Activity

- show EZH2 inhibition selectivity
- describe cell lines and culture conditions
- outline reagents and antibodies
- detail CRISPR-mediated CARM1 knockout and lentivirus infection
- describe various assays and experiments
- perform ChIP and bioinformatics analysis
- analyze RNA-seq and ChIP-seq data
- present results on CARM1 amplification and EZH2 inhibition
- discuss implications of EZH2 inhibition on CARM1-high EOC cells
- explore CARM1-expressing ovarian cancer
- identify EZH2 target genes regulated by CARM1
- validate regulation of EZH2 target genes by CARM1 and EZH2 inhibitor
- establish CARM1-mediated BAF155 methylation antagonizes EZH2
- test EZH2 inhibitor in vivo on CARM1-expressing tumors
- correlate tumor growth suppression with molecular pathways
- discuss implications for targeting EZH2 in CARM1-expressing cancers

